Manufacturer of Idrasil™, the first standardized medical cannabis, launches after 14 years of research and development, takes aim at U.S. pharmaceutical industry and its opioid epidemic. ANAHEIM, Calif., Sept. 17, 2024 /PRNewswire/ — C3 Pharmaceuticals, Inc., […]
The competition in follicular lymphoma is rapidly intensifying, with three CAR-T therapies and three bispecific antibodies now approved for relapsed or refractory patients. As both classes of treatments expand, the battle for dominance in this […]
– Designación de terapia innovadora para los comprimidos sublinguales de Sanbexin otorgada por la Administración de Alimentos y Medicamentos de Estados Unidos NANJING, China, 16 de septiembre de 2024 /PRNewswire/ — El 2 de septiembre […]
TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer Expansion Cohorts in Patients with Ovarian, Non-Small Cell Lung Cancer, and […]
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA, Sept. 14, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) today […]